Aug 2026· iScience· Vol 29· 0 citations· 34 references
Medicine
TL;DR
The findings elucidate the SEI1/HDAC1/FOXC1/p53 axis as a critical driver of myeloma progression and identify tiludronate disodium as a potential therapeutic agent.
Abstract
Summary SEI1 is overexpressed in multiple myeloma and correlates with poor prognosis. In this study, we identify SEI1 as a crucial driver of myeloma pathogenesis through a previously unrecognized mechanism: transcriptional inactivation of the tumor suppressor p53. Mechanistically, SEI1 forms a transcriptional complex with histone deacetylase 1 (HDAC1) and forkhead box C1 (FOXC1), which binds to the p53 promoter, decreases histone H3 lysine 27 acetylation (H3K27ac), and suppresses p53 transcription, thereby promoting myeloma cell proliferation. SEI1 enhances the stability of the HDAC1-FOXC1 interaction, further amplifying p53 repression. High-throughput virtual screening has identified tiludronate disodium as a potent inhibitor of FOXC1. Tiludronate disodium disrupts the HDAC1-FOXC1 interaction, restores H3K27ac enrichment and p53 expression, and suppresses myeloma growth both in vitro and in vivo, including a reduction of osteolytic lesions. These findings elucidate the SEI1/HDAC1/FOXC1/p53 axis as a critical driver of myeloma progression and identify tiludronate disodium as a potential therapeutic agent.
Functional studies reveal that YTHDC1 facilitates MM cell growth and survival in an m6A-dependent manner and highlight the YTHDC1-EP300 axis as a promising target for therapeutic intervention.
Yi-Fan Hou, Qi-Qi Shen, J. Qu et al.· Oncogene· 0 citations
A novel mechanistic insight is introduced into the pathogenesis of myeloma and bone deterioration and disruption of the ENO1–PTTG1 interaction is identified as a potential dual-targeting therapeutic strategy, demonstrating significant efficacy in curbing myeloma progression and osteolytic lesions.
Rui Liu, Ya-Zhu Huang, Z. Fang et al.· Cell Death & Disease· 0 citations
Regulation of oncogenic transcriptional programs in multiple myeloma requires the interplay of histone modifications, their writers and readers with lineage-affiliated transcription factors. The transcription factors IKZF1/3, IRF4 and MYC form an aberrant, myeloma-specific regulatory loop that drives myelomagenesis and...
P. Sabbattini, Nikolaos Trasanidis, J. Taslim et al.· Blood· 0 citations
Lung adenocarcinoma (LUAD) is one of the major subtypes of non-small cell lung cancer (NSCLC), but the molecular mechanisms underlying LUAD initiation and progression remain incompletely understood. In the present study, we identified TRIM46 as a key driver of LUAD progression. TRIM46 is significantly overexpressed i...
Shao-Kun Yu, Xiao Ke, Zhi-Li Liu et al.· Cell Death & Disease· 0 citations
The role of non-histone lysine methylation in tumorigenesis has attracted increasing attention, and the dysregulated “writers”, “erasers” and “readers” of it are promising therapeutic targets. In this study, we demonstrated that lysine-specific demethylase 4B (KDM4B) was significantly upregulated in renal cell carc...
Zi-Ran Dai, Ming-Xiao Zhang, Hao Zhou et al.· Cell Death & Disease· 0 citations
Pulmonary metastasis is the leading cause of mortality in osteosarcoma patients, yet the molecular mechanisms that sustain invasive malignancy within metastatic niches remain poorly understood. Through analysis of single-cell transcriptomic data from osteosarcoma lung metastases and clinical survival datasets, this s...
Jia-Min Zhang, Jia-Hui Guo, Xun-Rui Chen et al.· Cell Death & Disease· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
